Santhera Pharmaceuticals Holding AG (SANN) - Total Assets

Latest as of December 2025: CHF148.09 Million CHF ≈ $187.22 Million USD

Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SANN) holds total assets worth CHF148.09 Million CHF (≈ $187.22 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Santhera Pharmaceuticals Holding AG to assess how comfortably operating cash covers total debt obligations.

Santhera Pharmaceuticals Holding AG - Total Assets Trend (2006–2025)

This chart illustrates how Santhera Pharmaceuticals Holding AG's total assets have evolved over time, based on quarterly financial data. See what is Santhera Pharmaceuticals Holding AG's book value for net asset value and shareholders' equity analysis.

Santhera Pharmaceuticals Holding AG - Asset Composition Analysis

Current Asset Composition (December 2025)

Santhera Pharmaceuticals Holding AG's total assets of CHF148.09 Million consist of 54.2% current assets and 45.8% non-current assets.

Asset Category	Amount (CHF)	% of Total Assets
Cash & Equivalents	CHF0.00	15.2%
Accounts Receivable	CHF26.04 Million	17.6%
Inventory	CHF24.87 Million	16.8%
Property, Plant & Equipment	CHF0.00	0.0%
Intangible Assets	CHF63.94 Million	43.2%
Goodwill	CHF0.00	0.0%

Asset Composition Trend (2006–2025)

This chart illustrates how Santhera Pharmaceuticals Holding AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SANN market cap overview.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Santhera Pharmaceuticals Holding AG's current assets represent 54.2% of total assets in 2025, a decrease from 78.9% in 2006.
Cash Position: Cash and equivalents constituted 15.2% of total assets in 2025, down from 77.4% in 2006.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 43.0% of total assets, an increase from 19.0% in 2006.
Asset Diversification: The largest asset category is intangible assets at 43.2% of total assets.

Santhera Pharmaceuticals Holding AG Competitors by Total Assets

Key competitors of Santhera Pharmaceuticals Holding AG based on total assets are shown below.

Company	Country	Total Assets
Ascendis Pharma AS NASDAQ:ASND	USA	$2.01 Billion
ALTEOGEN Inc KQ:196170	Korea	₩729.47 Billion
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	USA	$1.29 Billion
Definium Therapeutics, Inc. NASDAQ:DFTX	USA	$440.10 Million
Neuren Pharmaceuticals Ltd AU:NEU	Australia	AU$331.25 Million
Galapagos N.V. AS:GLPG	Netherlands	€3.37 Billion
Blue Jet Healthcare Limited NSE:BLUEJET	India	Rs16.41 Billion
Inventiva S.A PA:IVA	France	€249.51 Million

Santhera Pharmaceuticals Holding AG - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.29	1.64	0.61
Quick Ratio	0.89	1.26	0.59
Cash Ratio	0.00	0.00	0.00
Working Capital	CHF18.07 Million	CHF29.67 Million	CHF-11.35 Million

Santhera Pharmaceuticals Holding AG - Advanced Valuation Insights

This section examines the relationship between Santhera Pharmaceuticals Holding AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	6.48
Latest Market Cap to Assets Ratio	1.64
Asset Growth Rate (YoY)	-2.9%
Total Assets	CHF148.09 Million
Market Capitalization	$243.45 Million USD

Valuation Analysis

Above Book Valuation: The market values Santhera Pharmaceuticals Holding AG's assets above their book value (1.64x), reflecting positive investor sentiment about the company's future prospects.

Slight Asset Contraction: Santhera Pharmaceuticals Holding AG's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Santhera Pharmaceuticals Holding AG (2006–2025)

The table below shows the annual total assets of Santhera Pharmaceuticals Holding AG from 2006 to 2025.

Year	Total Assets	Change
2025-12-31	CHF148.09 Million ≈ $187.22 Million	-2.89%
2024-12-31	CHF152.49 Million ≈ $192.79 Million	+39.09%
2023-12-31	CHF109.63 Million ≈ $138.60 Million	+72.03%
2022-12-31	CHF63.73 Million ≈ $80.57 Million	-30.06%
2021-12-31	CHF91.12 Million ≈ $115.20 Million	+2.74%
2020-12-31	CHF88.69 Million ≈ $112.12 Million	-22.92%
2019-12-31	CHF115.05 Million ≈ $145.46 Million	+4.31%
2018-12-31	CHF110.29 Million ≈ $139.44 Million	+0.47%
2017-12-31	CHF109.78 Million ≈ $138.79 Million	+20.91%
2016-12-31	CHF90.79 Million ≈ $114.79 Million	-22.50%
2015-12-31	CHF117.15 Million ≈ $148.11 Million	+410.58%
2014-12-31	CHF22.95 Million ≈ $29.01 Million	+135.67%
2013-12-31	CHF9.74 Million ≈ $12.31 Million	-46.75%
2012-12-31	CHF18.29 Million ≈ $23.12 Million	-64.86%
2011-12-31	CHF52.03 Million ≈ $65.79 Million	-33.94%
2010-12-31	CHF78.77 Million ≈ $99.58 Million	-16.83%
2009-12-31	CHF94.70 Million ≈ $119.73 Million	-16.15%
2008-12-31	CHF112.95 Million ≈ $142.80 Million	-21.66%
2007-12-31	CHF144.18 Million ≈ $182.28 Million	-11.22%
2006-12-31	CHF162.39 Million ≈ $205.31 Million	--

About Santhera Pharmaceuticals Holding AG

SW:SANN Switzerland Biotechnology

Market Cap

$254.57 Million

CHF201.36 Million CHF

Market Cap Rank

#15687 Global

#170 in Switzerland

Share Price

CHF14.16

Change (1 day)

-1.94%

52-Week Range

CHF9.58 - CHF18.54

All Time High

CHF1070.00